京新药业跌2.03%，成交额3646.17万元，主力资金净流入19.06万元

Core Viewpoint - Jingxin Pharmaceutical's stock price has shown volatility, with a year-to-date increase of 46.92% but a recent decline in the last 20 days by 6.82% [2] Group 1: Stock Performance - As of November 4, Jingxin Pharmaceutical's stock price was 18.32 CNY per share, with a market capitalization of 15.774 billion CNY [1] - The stock has experienced a 1.38% increase over the last five trading days and a 1.16% increase over the last 60 days [2] - The company has appeared on the trading leaderboard once this year, with a net buy of 1.11 billion CNY on July 4 [2] Group 2: Financial Performance - For the period from January to September 2025, Jingxin Pharmaceutical reported a revenue of 3.048 billion CNY, a year-on-year decrease of 5.00%, while the net profit attributable to shareholders was 576 million CNY, reflecting a slight increase of 0.10% [2] - Cumulative cash dividends since the company's A-share listing amount to 2.11 billion CNY, with 801 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 13.08% to 22,300, with an average of 32,438 circulating shares per shareholder, an increase of 15.05% [2] - The seventh largest circulating shareholder is Hong Kong Central Clearing Limited, holding 7.4588 million shares, down by 2.1904 million shares from the previous period [3] Group 4: Business Overview - Jingxin Pharmaceutical, established on February 13, 1999, and listed on July 15, 2004, specializes in the research, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [2] - The company's main business revenue composition is 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [2] - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and preparations, and is involved in various concept sectors including ophthalmology, cancer treatment, generic drugs, innovative drugs, and biomedicine [2]